Skip to main content

Kisspeptin Peptide: Research, Dosage & Effects on Testosterone

Kisspeptin is the neuropeptide that tells the brain to start the reproductive hormone cascade. It binds GPR54 on GnRH neurons, which triggers GnRH, which drives LH and FSH, which drive testosterone and ovarian follicle development. That upstream position is what makes it interesting and what makes most of the claims about it premature. The human evidence is real, peer-reviewed, and almost entirely from intravenous infusions in research settings. The protocols being sold online are not the protocols that were studied.

What Is Kisspeptin?

Kisspeptin is a family of neuropeptides produced by the KISS1 gene. The gene was first identified as a metastasis suppressor, which is where the name comes from, and its reproductive role was discovered later: researchers found that people with inactivating mutations in GPR54, the kisspeptin receptor, failed to go through puberty. That observation reframed kisspeptin as the switch that starts reproductive function.

The parent protein is cleaved into fragments named for their amino acid length: kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10. All of them share the same C-terminal decapeptide sequence and all activate GPR54. Kisspeptin-10 is the shortest fragment that retains full receptor activity, which is why it dominates both the research literature and the research-chemical market.

Unlike BPC-157 or other peptides with diffuse or contested mechanisms, kisspeptin has an unusually well-defined one. The receptor is known, the downstream cascade is mapped, and the loss-of-function phenotype in humans is unambiguous. The uncertainty is not about what it does. It is about whether the way people are using it produces any of the effects that were measured in trials.

How Kisspeptin Works: The HPG Cascade

The hypothalamic-pituitary-gonadal (HPG) axis runs in one direction. Kisspeptin neurons in the hypothalamus release kisspeptin onto GnRH neurons. Those neurons express GPR54, and activating it makes them fire and release GnRH in pulses. GnRH travels to the anterior pituitary and stimulates release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH drives Leydig cells in the testes to make testosterone, or drives ovulation in women. FSH supports spermatogenesis or follicular growth.

Two consequences follow from that architecture. First, kisspeptin only works if everything downstream is intact. Give it to someone whose pituitary cannot respond and nothing happens. Second, kisspeptin does not just increase GnRH output, it also appears to increase LH pulse frequency, and pulse pattern matters. The pituitary reads GnRH as a frequency-encoded signal, which is precisely why continuous GnRH agonist exposure paradoxically shuts the axis down instead of driving it.

Kisspeptin neurons are also where metabolic and stress signals feed into reproduction. Leptin, energy availability, and inflammatory signals converge on kisspeptin neurons, which is the mechanistic reason reproductive function collapses in states of low energy availability. This is also the link people draw between kisspeptin and PCOS, where kisspeptin signaling appears dysregulated.

Kisspeptin-10 vs Kisspeptin-54

Both fragments activate the same receptor. The practical difference is duration. Kisspeptin-10 has a half-life measured in minutes, so a bolus produces a sharp, short LH rise that decays quickly. Kisspeptin-54 persists substantially longer and produces a more sustained gonadotrophin response from a single administration.

A direct head-to-head study in healthy men compared intravenous kisspeptin-10, kisspeptin-54, and GnRH on gonadotrophin secretion. All three raised LH. Kisspeptin-54 produced the more prolonged response, consistent with its pharmacokinetics. Researchers select kisspeptin-10 when they want tight temporal control over the signal, and kisspeptin-54 when they want sustained exposure, such as in IVF trigger protocols.

Nearly everything sold online is kisspeptin-10, largely because a ten-residue peptide is cheap to synthesize. That matters: the fertility results that generate the most excitement about kisspeptin came predominantly from kisspeptin-54, not from the fragment most people are actually buying. Half-life differences across peptides are covered in our peptide half-life chart.

Kisspeptin and Testosterone: What the Data Shows

The headline number comes from a study of continuous kisspeptin-10 infusion in healthy men. At 4 micrograms per kilogram per hour for 22.5 hours, mean LH rose from 5.4 to 20.8 IU/L and serum testosterone rose from 16.6 to 24.0 nmol/L. In conventional units that is roughly 479 ng/dL to 692 ng/dL, an increase of about 45 percent. LH pulse frequency also increased.

Read the method before the result. That was a 22.5-hour continuous intravenous infusion with dose titrated to body weight, in a controlled research unit, in men with normal baseline function. It demonstrates that kisspeptin-10 can drive the axis. It does not demonstrate that a subcutaneous injection two or three times a week produces a durable testosterone increase, because that experiment has not been published.

The earlier first-in-human work by Dhillo and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 2005, used a 90-minute kisspeptin-54 infusion and found significant increases in LH, FSH, and testosterone against saline. That study established the effect exists in humans at all. Both studies come from the same Imperial College London program, which is the source of most published human kisspeptin data.

For comparison against approaches with an actual clinical track record, see peptides vs TRT and our gonadorelin guide. If the goal is a measured testosterone number, start with testosterone levels by age and a blood test rather than a research peptide.

The Response Differs Between Men and Women

Kisspeptin-10 does not produce the same effect in both sexes. A study specifically examining this found the reproductive hormone response to kisspeptin-10 shows sexual dimorphism in humans: men respond robustly with LH release across doses, while women show a response that depends heavily on menstrual cycle phase. Sensitivity is markedly higher in the preovulatory phase, when estrogen has primed the system, and lower in the follicular phase.

This has a practical implication that gets ignored. Dosing advice extrapolated from male data does not transfer to women, because the same dose at a different cycle point produces a different hormonal result. Related reading: peptides for women and peptide therapy for women.

Kisspeptin in Fertility and IVF

This is the application with the strongest clinical rationale. Standard IVF uses hCG to trigger final oocyte maturation, and hCG carries a risk of ovarian hyperstimulation syndrome (OHSS), which can be severe. Kisspeptin-54 has been tested as an alternative trigger, the idea being that it produces a more physiological, self-limiting LH surge rather than the prolonged stimulation hCG delivers.

Trials at Imperial College have evaluated kisspeptin-54 as an IVF trigger, including in women at high risk of OHSS. The direction of results has been encouraging enough to sustain a research program. It remains investigational: kisspeptin is not an approved fertility drug in the US or UK, and it is not available through fertility clinics as standard care.

Note again the fragment mismatch. The IVF work used kisspeptin-54. The product sold online is kisspeptin-10. See peptides for fertility for the broader picture, and hCG injections for the incumbent comparison.

Kisspeptin, Libido, and Emotional Processing

Kisspeptin receptors are not confined to the hypothalamus. They appear in limbic regions involved in emotion and reward, which prompted brain-imaging studies of kisspeptin administration and sexual and emotional processing. The Imperial group has reported that kisspeptin modulates activity in these regions in response to sexual and emotional stimuli, and has studied it in men with low sexual desire.

Two cautions. These are small mechanistic imaging studies, not efficacy trials with validated sexual function endpoints. And the effects were produced by intravenous infusion. The gap between an fMRI signal change under infusion and a durable improvement in libido from self-administered subcutaneous injection is enormous.

For a compound in this space with actual approval behind it, PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women: see PT-141. Also relevant: peptides for erectile dysfunction.

Kisspeptin Dosage: What Was Actually Studied

We are not going to publish a subcutaneous dosing schedule, because no validated one exists. What exists is the research record:

  • Kisspeptin-10, continuous IV: 4 mcg/kg/hour for 22.5 hours produced the LH and testosterone increases described above in healthy men.
  • Kisspeptin-10, IV bolus: dose-ranging studies used bolus doses in the low mcg/kg range, producing sharp LH rises that decayed within roughly an hour.
  • Kisspeptin-54, IV infusion: the 2005 first-in-human study used a 90-minute infusion; IVF trigger work used single subcutaneous doses of kisspeptin-54 in the mcg/kg range.

Everything circulating as a kisspeptin-10 protocol, typically something like 100 to 200 mcg subcutaneously a few times weekly, is extrapolation. It is not derived from a trial, and given the minutes-long half-life of kisspeptin-10, a subcutaneous bolus produces a transient pulse that clears long before the next dose. Whether repeated transient pulses accomplish anything durable is exactly what has not been tested.

For reconstituting research peptides generally, our reconstitution guide and peptide calculator cover the mechanics, and peptide storage covers handling.

Side Effects and Safety

Imperial College researchers have administered kisspeptin to more than 500 men and women across their trial program and report it as well tolerated, with no serious drug-related adverse events at studied doses. On its face that is a reassuring safety signal, and it is a larger human exposure base than most research peptides can claim.

The limitation is exposure duration. Those trials involved single administrations or exposures lasting hours to days. There is no published data on months of repeated kisspeptin dosing in humans. Absence of a long-term signal is not evidence of long-term safety; it is absence of the study.

The specific mechanistic concern is desensitization. The pituitary responds to GnRH pattern, not just amount. Continuous GnRH agonist exposure downregulates the axis, which is the entire basis for leuprolide as an androgen deprivation therapy. Kisspeptin infusion protocols show attenuation of LH response over prolonged continuous exposure. Whether intermittent kisspeptin dosing avoids that over months is unknown. The assumption that it does is doing a lot of unearned work in the community protocols.

General framing on this class of compound: are peptides safe.

Kisspeptin vs hCG vs Gonadorelin

All three touch the HPG axis, at different levels, with wildly different evidence bases.

  • hCG mimics LH and acts directly on the testes, bypassing the hypothalamus and pituitary. It works even when upstream signaling is fully suppressed. It is an approved drug with decades of use. See hCG on TRT.
  • Gonadorelin is synthetic GnRH, acting one level up, on the pituitary. It needs a responsive pituitary but not functioning kisspeptin neurons. Short half-life, pulsatile dosing. See our gonadorelin guide.
  • Kisspeptin acts at the top, on GnRH neurons themselves. It needs the entire downstream chain intact to do anything. It is the most physiological in theory and the least clinically established in practice.

The ordering is not accidental. The further upstream a compound acts, the more it depends on intact machinery below, and the less useful it is in exactly the suppressed-axis scenarios people most want to treat. Related: low testosterone symptoms.

Bottom Line

Kisspeptin has something most research peptides lack: a defined receptor, a mapped mechanism, an unambiguous human loss-of-function phenotype, and a real clinical trial program behind it. The biology is not in dispute.

What is in dispute is the translation. The testosterone result everyone cites came from a 22.5-hour intravenous infusion. The fertility results came from kisspeptin-54, not the kisspeptin-10 being sold. The libido findings are imaging studies under infusion. And the desensitization question, which determines whether repeated dosing works at all, is open.

A compound can be genuinely promising and still be a bad thing to buy from a research-chemical site and inject on a schedule nobody has tested. Kisspeptin is currently both.

Sources

  • George JT, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab, 2011. PubMed 21632807.
  • Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary-gonadal axis in human males. J Clin Endocrinol Metab, 2005.
  • The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab, 2011. PubMed 21976724 / PMC3232613.
  • Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. PMC4507333.
  • Imperial College London kisspeptin clinical trial program, including IVF trigger studies (ClinicalTrials.gov NCT01667406).

Frequently Asked Questions About Kisspeptin

Kisspeptin is a neuropeptide that binds the GPR54 receptor on GnRH neurons in the hypothalamus. Activating those neurons triggers GnRH release, which drives the pituitary to secrete LH and FSH, which in turn drive testosterone production in the testes and follicular development in the ovaries. It sits one level above GnRH in the reproductive hormone cascade, which is why it is often described as an upstream switch rather than a hormone that acts directly on the gonads.

In the most-cited human study, a continuous infusion of kisspeptin-10 at 4 micrograms per kilogram per hour for 22.5 hours raised mean LH from 5.4 to 20.8 IU/L and serum testosterone from 16.6 to 24.0 nmol/L in healthy men. That is roughly a 45 percent rise in testosterone. Important context: that result came from a continuous intravenous infusion in a research setting, not from a subcutaneous injection given a few times a week. Nobody has published data showing the same effect from the protocols circulating in peptide communities.

They are fragments of the same parent protein encoded by the KISS1 gene, and both activate GPR54. Kisspeptin-54 is longer and has a substantially longer half-life, so it produces a more sustained LH response. Kisspeptin-10 is the minimal active fragment with a half-life measured in minutes, which makes it useful when researchers want tight pharmacokinetic control. A direct head-to-head in healthy men found both raised gonadotrophins, with kisspeptin-54 producing the more prolonged effect. Most material sold to consumers is kisspeptin-10.

This is the central unresolved question. Continuous GnRH agonist exposure downregulates pituitary receptors and eventually suppresses LH, which is exactly how drugs like leuprolide work as chemical castration agents. Kisspeptin infusions also show tachyphylaxis in some protocols: the LH response attenuates over prolonged continuous exposure. Whether intermittent dosing avoids this in humans over months is not established. Anyone assuming kisspeptin is a desensitization-free alternative to GnRH is going beyond the published evidence.

Kisspeptin is not an FDA-approved drug and is not on the 503A bulks list, so licensed compounding pharmacies cannot legally compound it from bulk for patients. It is sold online labeled for research use only, which is a legal channel for the seller but not a legal pathway for human use. It was not among the seven peptides scheduled for the July 2026 Pharmacy Compounding Advisory Committee review. See our guide on whether peptides are legal for the full framework.

The theory is reasonable and the evidence is thin. Kisspeptin acts upstream of GnRH, so in principle it could restart a suppressed hypothalamic-pituitary-gonadal axis. But no published trial has tested kisspeptin for post-cycle recovery or as a TRT alternative in men with suppressed axes. The human data comes from healthy volunteers and from fertility populations. hCG and gonadorelin have far more clinical track record for axis support, imperfect as they are.

Across Imperial College trials involving more than 500 men and women, kisspeptin has been reported as well tolerated with no serious drug-related adverse events at the doses studied. Those trials were short: single infusions or exposures measured in hours to days. There is no published long-term human safety data. Because kisspeptin drives the reproductive axis, plausible concerns include effects on menstrual cycling in women and unpredictable gonadotrophin responses in people with existing endocrine conditions, but these are theoretical rather than documented.

They act at different levels. hCG mimics LH and stimulates the testes directly, bypassing the hypothalamus and pituitary entirely. Kisspeptin acts at the top of the cascade and requires an intact pituitary and functioning GnRH neurons to produce any downstream effect. That means hCG works even when the upstream axis is shut down, whereas kisspeptin does not. hCG is an approved drug with decades of clinical use; kisspeptin is a research compound.